List of Tables
Table 1. Global Viral Vector-Based Gene Therapy Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Viral Vector-Based Gene Therapy Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Viral Vector-Based Gene Therapy Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Viral Vector-Based Gene Therapy Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Viral Vector-Based Gene Therapy Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Viral Vector-Based Gene Therapy Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Viral Vector-Based Gene Therapy Drugs Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Viral Vector-Based Gene Therapy Drugs by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vector-Based Gene Therapy Drugs as of 2024)
Table 11. Global Viral Vector-Based Gene Therapy Drugs Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Viral Vector-Based Gene Therapy Drugs Companies Headquarters
Table 13. Global Viral Vector-Based Gene Therapy Drugs Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Viral Vector-Based Gene Therapy Drugs Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Viral Vector-Based Gene Therapy Drugs Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Viral Vector-Based Gene Therapy Drugs Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Viral Vector-Based Gene Therapy Drugs Revenue by Application (2026-2031) & (US$ Million)
Table 21. Viral Vector-Based Gene Therapy Drugs High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Viral Vector-Based Gene Therapy Drugs Growth Accelerators and Market Barriers
Table 25. North America Viral Vector-Based Gene Therapy Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Viral Vector-Based Gene Therapy Drugs Growth Accelerators and Market Barriers
Table 27. Europe Viral Vector-Based Gene Therapy Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Viral Vector-Based Gene Therapy Drugs Investment Opportunities and Key Challenges
Table 31. Central and South America Viral Vector-Based Gene Therapy Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Viral Vector-Based Gene Therapy Drugs Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Viral Vector-Based Gene Therapy Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. GSK Corporation Information
Table 35. GSK Description and Major Businesses
Table 36. GSK Product Features and Attributes
Table 37. GSK Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. GSK Revenue Proportion by Product in 2024
Table 39. GSK Revenue Proportion by Application in 2024
Table 40. GSK Revenue Proportion by Geographic Area in 2024
Table 41. GSK Viral Vector-Based Gene Therapy Drugs SWOT Analysis
Table 42. GSK Recent Developments
Table 43. MolMed Corporation Information
Table 44. MolMed Description and Major Businesses
Table 45. MolMed Product Features and Attributes
Table 46. MolMed Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. MolMed Revenue Proportion by Product in 2024
Table 48. MolMed Revenue Proportion by Application in 2024
Table 49. MolMed Revenue Proportion by Geographic Area in 2024
Table 50. MolMed Viral Vector-Based Gene Therapy Drugs SWOT Analysis
Table 51. MolMed Recent Developments
Table 52. GILD Corporation Information
Table 53. GILD Description and Major Businesses
Table 54. GILD Product Features and Attributes
Table 55. GILD Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. GILD Revenue Proportion by Product in 2024
Table 57. GILD Revenue Proportion by Application in 2024
Table 58. GILD Revenue Proportion by Geographic Area in 2024
Table 59. GILD Viral Vector-Based Gene Therapy Drugs SWOT Analysis
Table 60. GILD Recent Developments
Table 61. JW Therapeutics Corporation Information
Table 62. JW Therapeutics Description and Major Businesses
Table 63. JW Therapeutics Product Features and Attributes
Table 64. JW Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. JW Therapeutics Revenue Proportion by Product in 2024
Table 66. JW Therapeutics Revenue Proportion by Application in 2024
Table 67. JW Therapeutics Revenue Proportion by Geographic Area in 2024
Table 68. JW Therapeutics Viral Vector-Based Gene Therapy Drugs SWOT Analysis
Table 69. JW Therapeutics Recent Developments
Table 70. Sibiono Corporation Information
Table 71. Sibiono Description and Major Businesses
Table 72. Sibiono Product Features and Attributes
Table 73. Sibiono Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Sibiono Revenue Proportion by Product in 2024
Table 75. Sibiono Revenue Proportion by Application in 2024
Table 76. Sibiono Revenue Proportion by Geographic Area in 2024
Table 77. Sibiono Viral Vector-Based Gene Therapy Drugs SWOT Analysis
Table 78. Sibiono Recent Developments
Table 79. Latima Corporation Information
Table 80. Latima Description and Major Businesses
Table 81. Latima Product Features and Attributes
Table 82. Latima Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Latima Recent Developments
Table 84. Novartis Corporation Information
Table 85. Novartis Description and Major Businesses
Table 86. Novartis Product Features and Attributes
Table 87. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Novartis Recent Developments
Table 89. Bluebird Bio Corporation Information
Table 90. Bluebird Bio Description and Major Businesses
Table 91. Bluebird Bio Product Features and Attributes
Table 92. Bluebird Bio Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Bluebird Bio Recent Developments
Table 94. Thermo Fisher Scientific Corporation Information
Table 95. Thermo Fisher Scientific Description and Major Businesses
Table 96. Thermo Fisher Scientific Product Features and Attributes
Table 97. Thermo Fisher Scientific Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Thermo Fisher Scientific Recent Developments
Table 99. Intas Corporation Information
Table 100. Intas Description and Major Businesses
Table 101. Intas Product Features and Attributes
Table 102. Intas Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Intas Recent Developments
Table 104. BMS Corporation Information
Table 105. BMS Description and Major Businesses
Table 106. BMS Product Features and Attributes
Table 107. BMS Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. BMS Recent Developments
Table 109. Orchard Therapeutics Corporation Information
Table 110. Orchard Therapeutics Description and Major Businesses
Table 111. Orchard Therapeutics Product Features and Attributes
Table 112. Orchard Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Orchard Therapeutics Recent Developments
Table 114. Shanghai Sunway Biotech Corporation Information
Table 115. Shanghai Sunway Biotech Description and Major Businesses
Table 116. Shanghai Sunway Biotech Product Features and Attributes
Table 117. Shanghai Sunway Biotech Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. Shanghai Sunway Biotech Recent Developments
Table 119. uniQure Corporation Information
Table 120. uniQure Description and Major Businesses
Table 121. uniQure Product Features and Attributes
Table 122. uniQure Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. uniQure Recent Developments
Table 124. Spark Therapeutics Corporation Information
Table 125. Spark Therapeutics Description and Major Businesses
Table 126. Spark Therapeutics Product Features and Attributes
Table 127. Spark Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. Spark Therapeutics Recent Developments
Table 129. Raw Materials Key Suppliers
Table 130. Distributors List
Table 131. Market Trends and Market Evolution
Table 132. Market Drivers and Opportunities
Table 133. Market Challenges, Risks, and Restraints
Table 134. Research Programs/Design for This Report
Table 135. Key Data Information from Secondary Sources
Table 136. Key Data Information from Primary Sources
List of Figures
Figure 1. Viral Vector-Based Gene Therapy Drugs Product Picture
Figure 2. Global Viral Vector-Based Gene Therapy Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Retroviral Vector Product Picture
Figure 4. Adenovirus Vector Product Picture
Figure 5. Lentiviral Vector Product Picture
Figure 6. Others Product Picture
Figure 7. Global Viral Vector-Based Gene Therapy Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Hospital
Figure 9. Diagnostic and Testing Laboratories
Figure 10. Academic and Research Organizations
Figure 11. Others
Figure 12. Viral Vector-Based Gene Therapy Drugs Report Years Considered
Figure 13. Global Viral Vector-Based Gene Therapy Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Viral Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 15. Global Viral Vector-Based Gene Therapy Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 16. Global Viral Vector-Based Gene Therapy Drugs Revenue Market Share by Region (2020-2031)
Figure 17. Global Viral Vector-Based Gene Therapy Drugs Revenue Market Share Ranking (2024)
Figure 18. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 19. Retroviral Vector Revenue Market Share by Player in 2024
Figure 20. Adenovirus Vector Revenue Market Share by Player in 2024
Figure 21. Lentiviral Vector Revenue Market Share by Player in 2024
Figure 22. Others Revenue Market Share by Player in 2024
Figure 23. Global Viral Vector-Based Gene Therapy Drugs Revenue Market Share by Type (2020-2031)
Figure 24. Global Viral Vector-Based Gene Therapy Drugs Revenue Market Share by Application (2020-2031)
Figure 25. North America Viral Vector-Based Gene Therapy Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 26. North America Top 5 Players Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) in 2024
Figure 27. North America Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) by Type (2020 - 2031)
Figure 28. North America Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) by Application (2020-2031)
Figure 29. US Viral Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 30. Canada Viral Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 31. Mexico Viral Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 32. Europe Viral Vector-Based Gene Therapy Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 33. Europe Top 5 Players Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) in 2024
Figure 34. Europe Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) by Type (2020-2031)
Figure 35. Europe Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) by Application (2020-2031)
Figure 36. Germany Viral Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 37. France Viral Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 38. U.K. Viral Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 39. Italy Viral Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 40. Russia Viral Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 42. Asia-Pacific Top 8 Players Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) in 2024
Figure 43. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) by Type (2020-2031)
Figure 44. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) by Application (2020-2031)
Figure 45. Indonesia Viral Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 46. Japan Viral Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 47. South Korea Viral Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 48. Australia Viral Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 49. India Viral Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 50. Indonesia Viral Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 51. Vietnam Viral Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 52. Malaysia Viral Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 53. Philippines Viral Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 54. Singapore Viral Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 55. Central and South America Viral Vector-Based Gene Therapy Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 56. Central and South America Top 5 Players Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) in 2024
Figure 57. Central and South America Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) by Type (2020-2031)
Figure 58. Central and South America Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) by Application (2020-2031)
Figure 59. Brazil Viral Vector-Based Gene Therapy Drugs Revenue (2020-2025) & (US$ Million)
Figure 60. Argentina Viral Vector-Based Gene Therapy Drugs Revenue (2020-2025) & (US$ Million)
Figure 61. Middle East and Africa Viral Vector-Based Gene Therapy Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 62. Middle East and Africa Top 5 Players Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) in 2024
Figure 63. South America Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) by Type (2020-2031)
Figure 64. Middle East and Africa Viral Vector-Based Gene Therapy Drugs Revenue (US$ Million) by Application (2020-2031)
Figure 65. GCC Countries Viral Vector-Based Gene Therapy Drugs Revenue (2020-2025) & (US$ Million)
Figure 66. Israel Viral Vector-Based Gene Therapy Drugs Revenue (2020-2025) & (US$ Million)
Figure 67. Egypt Viral Vector-Based Gene Therapy Drugs Revenue (2020-2025) & (US$ Million)
Figure 68. South Africa Viral Vector-Based Gene Therapy Drugs Revenue (2020-2025) & (US$ Million)
Figure 69. Viral Vector-Based Gene Therapy Drugs Industry Chain Mapping
Figure 70. Channels of Distribution (Direct Vs Distribution)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
